Please enable JavaScript to continue using this application.

Compare $DNLI vs $PURR | Chartloom

Compare

$DNLI vs $PURR

Denali Therapeutics Inc · Hyperliquid Strategies Inc

DNLI

Denali Therapeutics Inc

PURR

Hyperliquid Strategies Inc

Compare $DNLI vs $PURR

Comparing Denali Therapeutics Inc and Hyperliquid Strategies Inc

DNLIDenali Therapeutics Inc

PURRHyperliquid Strategies Inc

DNLIDenali Therapeutics Inc

Market cap

$3.09B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

37.36x

Rev growth (TTM)

—

YTD performance

19.5%

52W performance

24.3%

FCF yield

-15.2%

PURRHyperliquid Strategies Inc

Market cap

$1.50B

P/E (TTM)

—

Forward P/E (NTM)

54.46x

Forward P/S (NTM)

31.07x

Rev growth (TTM)

—

YTD performance

223.0%

52W performance

184.9%

FCF yield

-21.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DNLI

PURR

Detailed metrics comparison

DNLI

Denali Therapeutics Inc

PURR

Hyperliquid Strategies Inc

Market Cap

DNLI$3.09B

PURR$1.50B

Enterprise Value

DNLI$2.89B

PURR$1.36B

Price

DNLI$19.45

PURR$11.11

P/E Ratio

DNLIN/A

PURRN/A

P/S Ratio

DNLI856.52x

PURR478.45x

EV/Sales

DNLI802.15x

PURR434.33x

EV/EBITDA

DNLI88.01x

PURR0.00x

P/B Ratio

DNLI3.83x

PURR3.80x

P/FCF Ratio

DNLIN/A

PURRN/A

EV/FCF

DNLI-6.16x

PURR-4.21x

PEG Ratio

DNLIN/A

PURRN/A

Forward P/E (NTM)

DNLIN/A

PURR54.46x

Forward P/S (NTM)

DNLI37.36x

PURR31.07x

Revenue (TTM)

DNLI$4M

PURR$3M

Revenue Growth (YoY)

DNLIN/A

PURRN/A

Forward Rev Growth

DNLI237.9%

PURR32.1%

Gross Margin (TTM)

DNLI97.4%

PURR0.0%

Operating Margin (TTM)

DNLI0.0%

PURR0.0%

EBITDA Margin (TTM)

DNLI-14617.3%

PURR-41799.5%

Net Margin (TTM)

DNLI-14191.2%

PURR-44523.2%

FCF Margin (TTM)

DNLI-13013.7%

PURR-10320.0%

Net Income (TTM)

DNLI$-511M

PURR$-1.39B

FCF (TTM)

DNLI$-469M

PURR$-323M

EPS (TTM)

DNLI-$2.73

PURR-$8.94

ROE (TTM)

DNLI-5527.0%

PURR0.0%

ROA (TTM)

DNLI-4424.0%

PURR0.0%

ROIC (TTM)

DNLI-5494.0%

PURR0.0%

Cash

DNLI$202M

PURR$138M

Debt

DNLI$6M

PURR$0

Net Cash/Debt

DNLI$196M

PURR$138M

Current Ratio (TTM)

DNLI8.37x

PURR41.62x

Quick Ratio (TTM)

DNLI7.93x

PURR37.77x

Debt/Equity (TTM)

DNLI0.01x

PURR0.00x

Debt/Assets (TTM)

DNLI0.0%

PURR0.0%

Interest Coverage (TTM)

DNLIN/A

PURRN/A

Net Debt/EBITDA (TTM)

DNLI0.00x

PURR0.00x

Beta

DNLI1.06

PURR1.09

52W Performance

DNLI24.3%

PURR184.9%

YTD Performance

DNLI19.5%

PURR223.0%

% from 52W High

DNLI-28.8%

PURR-24.7%

% from 52W Low

DNLI41.5%

PURR269.1%

Asset Turnover (TTM)

DNLI0.00x

PURR0.00x

FCF Yield (TTM)

DNLI-15.2%

PURR-21.6%

Earnings Yield (TTM)

DNLI-16.6%

PURR-93.1%

Dividend Yield (TTM)

DNLIN/A

PURRN/A

Rule of 40

DNLI-13,013.7

PURR-10,320.0

EV/GP/RG

DNLI0.28

PURRN/A

Ticker research

View DNLI research View PURR research

Metric	DNLI Denali Therapeutics Inc	PURR Hyperliquid Strategies Inc
Market & Valuation
Market Cap	$3.09B	$1.50B
Enterprise Value	$2.89B	$1.36B
Price	$19.45	$11.11
P/E Ratio	N/A	N/A
P/S Ratio	856.52x	478.45x
EV/Sales	802.15x	434.33x
EV/EBITDA	88.01x	0.00x
P/B Ratio	3.83x	3.80x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.16x	-4.21x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	54.46x
Forward P/S (NTM)	37.36x	31.07x
Revenue & Growth
Revenue (TTM)	$4M	$3M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	237.9%	32.1%
Profitability
Gross Margin (TTM)	97.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-14617.3%	-41799.5%
Net Margin (TTM)	-14191.2%	-44523.2%
FCF Margin (TTM)	-13013.7%	-10320.0%
Net Income (TTM)	$-511M	$-1.39B
FCF (TTM)	$-469M	$-323M
EPS (TTM)	-$2.73	-$8.94
ROE (TTM)	-5527.0%	0.0%
ROA (TTM)	-4424.0%	0.0%
ROIC (TTM)	-5494.0%	0.0%
Financial Health
Cash	$202M	$138M
Debt	$6M	$0
Net Cash/Debt	$196M	$138M
Current Ratio (TTM)	8.37x	41.62x
Quick Ratio (TTM)	7.93x	37.77x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.06	1.09
52W Performance	24.3%	184.9%
YTD Performance	19.5%	223.0%
% from 52W High	-28.8%	-24.7%
% from 52W Low	41.5%	269.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-15.2%	-21.6%
Earnings Yield (TTM)	-16.6%	-93.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-13,013.7	-10,320.0
EV/GP/RG	0.28	N/A
Ticker research	View DNLI research	View PURR research

Valuation

P/S Ratio

PURR

478.45x

DNLI

856.52x

EV/FCF

DNLI

-6.16x

PURR

-4.21x

Growth & revenue

Forward Revenue Growth

DNLI

237.9%

PURR

32.1%

Profitability & performance

Gross Margin

DNLI

97.4%

PURR

0.0%

ROE

PURR

0.0%

DNLI

-5527.0%

FCF Yield %

DNLI

-15.2%

PURR

-21.6%

52-Week Performance

PURR

184.9%

DNLI

24.3%

Detailed metrics comparison

DNLI

Denali Therapeutics Inc

PURR

Hyperliquid Strategies Inc

Market Cap

DNLI$3.09B

PURR$1.50B

Enterprise Value

DNLI$2.89B

PURR$1.36B

Price

DNLI$19.45

PURR$11.11

P/E Ratio

DNLIN/A

PURRN/A

P/S Ratio

DNLI856.52x

PURR478.45x

EV/Sales

DNLI802.15x

PURR434.33x

EV/EBITDA

DNLI88.01x

PURR0.00x

P/B Ratio

DNLI3.83x

PURR3.80x

P/FCF Ratio

DNLIN/A

PURRN/A

EV/FCF

DNLI-6.16x

PURR-4.21x

PEG Ratio

DNLIN/A

PURRN/A

Forward P/E (NTM)

DNLIN/A

PURR54.46x

Forward P/S (NTM)

DNLI37.36x

PURR31.07x

Revenue (TTM)

DNLI$4M

PURR$3M

Revenue Growth (YoY)

DNLIN/A

PURRN/A

Forward Rev Growth

DNLI237.9%

PURR32.1%

Gross Margin (TTM)

DNLI97.4%

PURR0.0%

Operating Margin (TTM)

DNLI0.0%

PURR0.0%

EBITDA Margin (TTM)

DNLI-14617.3%

PURR-41799.5%

Net Margin (TTM)

DNLI-14191.2%

PURR-44523.2%

FCF Margin (TTM)

DNLI-13013.7%

PURR-10320.0%

Net Income (TTM)

DNLI$-511M

PURR$-1.39B

FCF (TTM)

DNLI$-469M

PURR$-323M

EPS (TTM)

DNLI-$2.73

PURR-$8.94

ROE (TTM)

DNLI-5527.0%

PURR0.0%

ROA (TTM)

DNLI-4424.0%

PURR0.0%

ROIC (TTM)

DNLI-5494.0%

PURR0.0%

Cash

DNLI$202M

PURR$138M

Debt

DNLI$6M

PURR$0

Net Cash/Debt

DNLI$196M

PURR$138M

Current Ratio (TTM)

DNLI8.37x

PURR41.62x

Quick Ratio (TTM)

DNLI7.93x

PURR37.77x

Debt/Equity (TTM)

DNLI0.01x

PURR0.00x

Debt/Assets (TTM)

DNLI0.0%

PURR0.0%

Interest Coverage (TTM)

DNLIN/A

PURRN/A

Net Debt/EBITDA (TTM)

DNLI0.00x

PURR0.00x

Beta

DNLI1.06

PURR1.09

52W Performance

DNLI24.3%

PURR184.9%

YTD Performance

DNLI19.5%

PURR223.0%

% from 52W High

DNLI-28.8%

PURR-24.7%

% from 52W Low

DNLI41.5%

PURR269.1%

Asset Turnover (TTM)

DNLI0.00x

PURR0.00x

FCF Yield (TTM)

DNLI-15.2%

PURR-21.6%

Earnings Yield (TTM)

DNLI-16.6%

PURR-93.1%

Dividend Yield (TTM)

DNLIN/A

PURRN/A

Rule of 40

DNLI-13,013.7

PURR-10,320.0

EV/GP/RG

DNLI0.28

PURRN/A

Ticker research

View DNLI research View PURR research

Metric	DNLI Denali Therapeutics Inc	PURR Hyperliquid Strategies Inc
Market & Valuation
Market Cap	$3.09B	$1.50B
Enterprise Value	$2.89B	$1.36B
Price	$19.45	$11.11
P/E Ratio	N/A	N/A
P/S Ratio	856.52x	478.45x
EV/Sales	802.15x	434.33x
EV/EBITDA	88.01x	0.00x
P/B Ratio	3.83x	3.80x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.16x	-4.21x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	54.46x
Forward P/S (NTM)	37.36x	31.07x
Revenue & Growth
Revenue (TTM)	$4M	$3M
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	237.9%	32.1%
Profitability
Gross Margin (TTM)	97.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-14617.3%	-41799.5%
Net Margin (TTM)	-14191.2%	-44523.2%
FCF Margin (TTM)	-13013.7%	-10320.0%
Net Income (TTM)	$-511M	$-1.39B
FCF (TTM)	$-469M	$-323M
EPS (TTM)	-$2.73	-$8.94
ROE (TTM)	-5527.0%	0.0%
ROA (TTM)	-4424.0%	0.0%
ROIC (TTM)	-5494.0%	0.0%
Financial Health
Cash	$202M	$138M
Debt	$6M	$0
Net Cash/Debt	$196M	$138M
Current Ratio (TTM)	8.37x	41.62x
Quick Ratio (TTM)	7.93x	37.77x
Debt/Equity (TTM)	0.01x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.06	1.09
52W Performance	24.3%	184.9%
YTD Performance	19.5%	223.0%
% from 52W High	-28.8%	-24.7%
% from 52W Low	41.5%	269.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-15.2%	-21.6%
Earnings Yield (TTM)	-16.6%	-93.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-13,013.7	-10,320.0
EV/GP/RG	0.28	N/A
Ticker research	View DNLI research	View PURR research